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Abstract
Chronic rejection is the major cause of long-term heart allograft failure, characterized by tissue infiltration by recipient T
cells with indirect allospecificity. Phosphoinositol-3-kinase p110d is a key mediator of T cell receptor signaling, regulating
both T cell activation and migration of primed T cells to non-lymphoid antigen-rich tissue. We investigated the effect of
genetic or pharmacologic inactivation of PI3K p110d on the development of chronic allograft rejection in a murine model in
which HY-mismatched male hearts were transplanted into female recipients. We show that suppression of p110d activity
significantly attenuates the development of chronic rejection of heart grafts in the absence of any additional
immunosuppressive treatment by impairing the localization of antigen-specific T cells to the grafts, while not inducing
specific T cell tolerance. p110d pharmacologic inactivation is effective when initiated after transplantation. Targeting p110d
activity might be a viable strategy for the treatment of heart chronic rejection in humans.
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Introduction
Chronic rejection is the main cause of late heart allograft failure
and the leading cause of death in patients surviving more than
1 year after transplantation [1,2]. Prominent features of chronic
heart graft rejection include proximal coronary artery vasculo-
pathy, occlusion, and eventually loss of cardiac function [1–3].
These lesions are associated with substantial parenchymal
infiltration by T cells [4]. Host immunity – particularly indirect
alloresponses mediated by CD4
+ T cells, as well as antibody-
mediated immune responses – to processed fragments of donor
major histocompatibility antigens (MHC) and to minor histocom-
patibility antigens (mHC) have been linked to the development of
chronic heart allograft rejection [5–15].
Besides antigen-induced activation, the development of immune
responses requires active mechanisms of recruitment of antigen-
specific primed T cells into antigenic sites. We and others have
shown that T cell receptor (TCR) engagement by antigen-
presenting endothelium leads to the migration of antigen-specific
memory T cells to non-lymphoid antigen-rich target tissue following
priming [16–20]. This effect is required for the development of a
number of T cell-mediated diseases in mice [20–22]. The effect of
TCR ligation on T lymphocyte motility is likely to engage signaling
pathways linking TCR triggering to the cytoskeleton. Class IA
phosphoinositide 3-kinases (PI3Ks) are a family of p85/p110
heterodimeric lipid kinases that generate second messenger signals
(e.g., PIP3) downstream of tyrosine kinases, thereby controlling
various cell functions, including motility. PI3K p110d subunit
expression is restricted to hematopoietic cells [23]. Following TCR
triggering, p110d is recruited by adaptor proteins [24,25]. Previous
studies have shown that miceexpressing a catalyticallyinactive form
of p110d (P110d
D910A) display attenuated T cell-mediated immu-
nity, although p110d
D910A mice can be primed against nominal
antigens [26]. We have recently shown that, while chemotaxis and
constitutive trafficking of memory T lymphocytes with impaired
p110d activity are unaffected, these T cells are not susceptible to
TCR-mediated T cell recruitment to antigenic sites, which they fail
to infiltrate [21].
In this study, we have investigated the effect of PI3K p110d
inactivation on the development of chronic rejection in a murine
model of HY-mismatched heart allograft. We show that the
establishment of chronic rejection is significantly attenuated in
mice lacking p110d activity in the absence of any additional
immunosuppressive treatment. The therapeutic effects of p110d
inhibition correlated with impaired localization of HY-specific
memory T cells to the allografts, but did not induce T cell
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32892tolerance. Importantly, PI3K p110d pharmacologic inactivation is
effective even when initiated after transplantation. We propose that
selective PI3K p110d inhibitors can be developed into an effective
therapeutic tool to control chronic heart allograft rejection.
Results
Genetic abrogation of PI3K p110d–signaling preventsT-
cell-mediated chronic heart allograft rejection
PI3K p110d has been shown to play a critical and non-
redundant role in the activation and differentiation of naive T cells
[27]. We therefore sought to investigate the effect of inhibition of
PI3K p110d signaling on the development of immune-mediated
mechanisms of chronic heart allograft rejection. A well-established
model involving transplantation of HY-mismatched heart allo-
grafts, in which grafts develop pathological features of chronic
rejection over time [28], was adapted for this study. Development
of pathology in this model is strictly T cell-dependent, antibody-
independent [29], and occurs without cessation of the heartbeat
[28]. For this reason, histopathologic assessments, rather than
survival time points, are provided.
Recipient female WT and p110d
D910A mutant mice (bearing an
inactive form of p110d [26]) received either male (antigenic) or
female (non-antigenic control) WT hearts. 23 days after trans-
plant, both transplanted and native hearts were harvested and
stained with hematoxilin/eosin (HE, representative images in
Figure S1), and Miller’s elastin combined with SMC alpha actin
immuno-staining (Figure 1A). This time point was selected based
on previous monitoring of pathology development (data not
shown) and license constraints.
As it is shown in Figure 1, heart allografts placed into
p110d
D910A female recipients were protected from the develop-
ment of vasculopathy as assessed by histopathologic criteria.Co-
staining of elastine end SMC alpha actin revealed early signs of
vasculopathy (narrowing of the lumen and perivascular prolifer-
ation of SMC [30]) in female WT recipient of male hearts, which
was inhibited in p110d
D910A female recipients (Figure 1A–B). HE
staining of the tissues revealed severe inflammatory lesions in WT
female recipients of male hearts, which were significantly
attenuated in p110d
D910A female recipients (Figure 1C and
Figure S1). Female graft and native hearts were free of disease.
Graft infiltration by T cells and macrophages was assessed by
immunostaining with FITC-conjugated anti-CD3 and PE-conju-
gated anti-MAC2 antibodies. As shown in Figure 1D (represen-
tative tissue images from each group) and Figure 1E (mean T cell
infiltration 6 SD), T cell infiltration of male heart grafted into
female p110d
D910A mutants was significantly reduced compared
with that observed in transplanted male heart grafted into WT
female recipients. No difference in T cell infiltration of either
female-derived heart grafts or native hearts was observed.
Interestingly, no significant difference in the number of infiltrating
macrophages was observed in any of the combinations tested.
Although p110d has been shown to affect B cell chemotaxis [31],
these data suggest that T cell p110d activity is selectively targeted
in this model, in which the development of chronic rejection is
strictly T cell-dependent and B cell-independent [28].
PI3K p110d inhibition does not induce T cell tolerance
PI3K p110d has been reported to contribute to T-cell activation
and differentiation [23,26]. We therefore sought to investigate
whether the lack of PI3K p110d activity led to loss of
responsiveness by HY-specific T cells following transplantation.
Splenocytes from female WT and p110d
D910A recipients were
harvested 23 days after heart transplantation. T cells were
cultured with increasing concentrations of Dby or Uty HY epitope
peptides for 48 hours, followed by assessment of thymidine
incorporation. As shown in Figure 2, both WT and p110d
D910A
T cells proliferated in response to HY-derived peptides, suggesting
that antigen-specific T cell responsiveness was maintained in mice
which did not develop chronic rejection as a result of PI3K p110d
inactivation.
PI3K p110d is required for male heart graft infiltration by
HY-specific T cells
Antigen presentation by graft endothelium has previously been
shown to be instrumental to T cell infiltration and rejection of HY-
mismatched allografts [21,28].
Given that PI3K P110d inactivation did not lead to antigen-
specific T cell tolerance, we sought to investigate whether the
protective effect of abrogation of PI3K p110d signaling selectively
prevented antigen-dependent T cell recruitment to HY-mis-
matched heart graft. C57BL/6 female mice received a syngeneic
male (HY-mismatched) or female (non-antigenic) heart transplant.
On day 15 post-heart-grafting (i.e. once a memory T cell response
is physiologically established[32]), PKH26-labelled HY-specific
H2-A
b-restricted CD4
+ WT and CFSE-labeled HY-specific H2-
A
b-restricted p110d
D910A CD4
+ T cells (10
7/mouse) were injected
i.v. into female recipients of a WT male heart. The presence of
labeled T cells in both transplanted and native hearts was analyzed
24 hours later by wide-field fluorescence microscopy.
As shown in Figure 3, WT T cells promptly infiltrated male (A)
but not female-derived (B) heart grafts, while p110d
D910A T cell
localization to male transplanted hearts was significantly reduced
(A). These results demonstrated that PI3K p110d activity is
required for efficient access of HY-specific T cells to male heart
grafts. Interestingly, some T cell infiltration was observed in native
hearts of both WT and p110d
D910A recipients of male hearts,
possibly driven by non-specific inflammation induced by the
allograft, which was nevertheless unable to induce pathology.
PI3K p110d is not required for constitutive trafficking by
memory HY-specific T cells
We have previously suggested that lack of p110d activity
specifically affects antigen-driven migration, but not constitutive
memory T cell trafficking [21]. The chronic rejection model
allowed us to investigate whether this observation holds true in the
presence of inflammation. We therefore assessed the migration of
HY-specific T cells in sites of constitutive homing in C57BL/6
female recipients of a syngeneic male heart. On day 15 post-
grafting, PKH26-labelled HY-specific H2-A
b-restricted CD4
+ WT
and CFSE labeled HY-specific H2-A
b-restricted p110d
D910A T
cells (10
7/mouse) were injected i.v. into female recipients of a WT
male heart. T cell localization in the liver, kidney, lymph node,
spleen and gut were assessed 24 hours later by wide-field
fluorescence microscopy.
As shown in Figure 4, both WT and p110d
D910A T cells re-
circulated normally and could be detected in the liver, kidney,
lymph node, and spleen of recipient mice in similar numbers.
Notably, WT and p110d
D910A T cells displayed similar patterns of
distribution within the various organs and localized in the liver and
kidney in a scattered pattern, while they clustered in restricted
areas in lymph nodes. Some T cell infiltration was observed in
native hearts, irrespective of p110d activity. These observations
further confirm that p110d signaling selectively regulates T cell
migration to tissues that do express cognate antigen and it is not
required for constitutive trafficking of T cells.
p110delta Blockade Inhibits Allograft Rejection
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mismatched heart allograft recipients inhibits the
development of chronic heart allograft rejection
We have previously shown that PI3K p110d inhibition
selectively targets memory T cell trafficking [21]. This opens the
possibility that targeting PI3K p110d might be effective in a
therapeutic regime. We therefore investigated whether pharma-
cologic inactivation of PI3K P110d delivered after transplantation
at a time when the immune response is already established could
prevent the development of chronic rejection. Recipient female
WT mice received either syngeneic male or female heart grafts.
After 7 days, the selective PI3K p110d inhibitor IC87114 (60mg/
kg/day) or vehicle control was administered i.p. daily for 15 days.
Mice were sacrificed 24 hours after the last treatment (day 23).
Both transplanted and native hearts were harvested for analysis.
As it is shown in figure 5A, histological analysis showed that
treatment with PI3K p110d inhibitor IC87114 prevented the
development of pathological signs of chronic rejection (representa-
tive images are depicted in Figure S2 panel A). Similarly, T cell
infiltration of male heart grafted into WT female mice treated with
IC87114 was significantly reduced compared to that observed in
transplanted male heart grafted into WT recipient female mice
treated with vehicle control (Figure 5B and Figure S2 panel B). No
significant differences in T cell infiltrates were observed in either
female-to-female transplanted heart grafts or native hearts.
Macrophage infiltrates were often observed, but were of similar
magnitude in any donor to recipient combination tested, irrespec-
tive of the development of pathology.
Similarly to what we observed in p110d
D910A recipients of male
hearts, T cells obtained from WT female recipients treated with or
Figure 1. Genetic abrogation of PI3K p110d signaling prevents T-cell-mediated chronic heart allograft rejection. Recipient female WT
and p110d
D910A mutant mice received either male or female heart. Both transplanted and native hearts were harvested 23 days after transplant. (A)
Tissue sections were stained with Miller’s elastin followed by immunoperoxidase staining for SMCs using rabbit monoclonal antibody to mouse SMC
alpha -actin, then counterstained with hematoxylin. Luminal occlusion was evaluated by tracing the cross-section of each vessel’s internal elastic
lamina and lumen using software in two transverse sections per graft. Each panel shows a representative tissue image. Magnification: 20x. (B) The
mean percentage luminal occlusion 6 SD observed in 3 samples obtained from each recipient (at least 3 animals/group) is shown. *p,0.03 (C) The
mean histopathological scores 6 SD of transplanted hearts stained with HE observed in 3 samples obtained from each recipient (at least 3 animals/
group) is shown. 0, no inflammation; 1, light focal lymphohistocytic infiltrate; 2, moderate focal lymphohistocytic infiltrate with myocardial
involvement; 3, moderate to severe inflammation with focal vasculopathy and myocyte degeneration; 4, severe inflammation, vasculopathy and
myocardial fiber loss. **p,0.01. (D) Tissue sections were stained with FITC-labelled anti-CD3 antibody and PE-labelled anti-MAC2 antibody. Each
panel shows a representative tissue image. Magnification: 20x. (E) The mean T cell or macrophage infiltration 6 SD observed in 3 samples obtained
from each recipients (at least 3 animals/group) is shown. *p,0.05.
doi:10.1371/journal.pone.0032892.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32892Figure 2. Loss of PI3K p110d activity does not induce T cell tolerance. Recipient female WT and p110d
D910A mutant mice received male WT
transplanted heart. 60 days after transplant, splenocytes from either recipient WT or p110d
D910A mutant mice were incubated with different
concentrations of Dby and Uty HY peptide epitopes for 48 hours, followed by pulsing with [
3H] thymidine to assess T cell proliferation.
doi:10.1371/journal.pone.0032892.g002
Figure 3. PI3K p110d is required for heart graft infiltration by antigen-specific T cells. PKH26-labelled HY-specific H2-A
b-restricted CD4
+
WT and CFSE labelled HY-specific H2-A
b-restricted p110d
D910A T cells were injected i.v. into female mice transplanted with either male (A) or female
(B) syngeneic heart. T cell localization in the transplanted heart and native heart were assessed 24 hours later by wide-field fluorescence microscopy.
Tissue infiltration was quantified by randomly selecting ten 610-magnified fields from tissue samples obtained from each mouse from all the
experimental groups and assessing the number of fluorescent cells in each field. Each panel shows a representative tissue image. The mean T cell
infiltration 6 SD observed in samples from at least 3 animals is shown. Magnification: 10x. *p,0.05.
doi:10.1371/journal.pone.0032892.g003
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Uty epitopes, suggesting that IC87114 treatment did not affect
T cell responsiveness (Figure S3).
Finally, we sought to establish whether, like genetic inactivation,
pharmacological inhibition of P110d selectively affects localization
of specific T cells to the heart allograft. Recipient female WT mice
received either syngeneic male or female heart grafts. On day 15
post-heart-grafting, PKH26-labelled HY-specific H2-A
b-restricted
CD4
+ WT and CD4
+ WT treated with IC87114 (5mM, 1 hour at
37uC) (10
7/mouse) were injected i.v. into female mice recipients of
syngeneic male or female-derived hearts. The presence of labeled T
cells in both transplanted and native hearts were analyzed 24 hours
later by wide-field fluorescence microscopy. As shown in Figure 5C,
untreated T cells promptly localized to male heart grafts, unlike
CD4
+ WT T cells treated with IC87114. No difference in T cell
infiltration was observed in female heart grafts or native hearts.
These results suggest that pharmacologic PI3K p110d inactivation
is effective at inhibiting access of activated HY-specific T cells to
mHC-mismatched heart grafts in a therapeutic regimen.
PI3K p110d inactivation does not prevent rejection of HY-
mismatched skin
Immune-mediated rejection of vascularized (heart) and non-
vascularized (skin) allografts relies upon different mechanisms
[21,28,33,34]. Having shown that PI3K p110d inactivation either
by genetic mutation or pharmacological inhibition resulted in
inhibition of chronic rejection of male heart grafts, we assessed the
effect of PI3K p110d inactivation in a model of HY-mismatched
skin transplantation. Recipient female WT or p110d
D910A mice
received WT male skin grafts, and the occurrence of rejection was
monitored. Alternatively, WT female recipients of a syngeneic
male skin graft were treated daily with PI3K p110d inhibitor
IC87114 at 60mg/kg/day or vehicle control 7 days after
transplantation until rejection. As it is shown in Figure 6A and
6B, neither genetic nor pharmacological inhibition of PI3K p110d
activity led to enhanced skin graft survival. Splenocytes from all
groups proliferated equally well to both the HY Dby and Uty
epitopes (Figure S4).
We further investigated the ability of HY-specific T cells to
infiltrate skin grafts. Both male and female skins were grafted onto
female recipient mice. On day 20 post-grafting, PKH26-labelled
HY-specific H2-A
b-restricted CD4
+ WT and CFSE labelled HY-
specific H2-A
b-restricted p110d
D910A T cells were injected i.v. into
recipient mice. In parallel experiment, HY-specific WT T cells
were treated with IC87114 (5mM, 1 hour at 37uC) (10
7/mouse) or
vehicle (DMSO) before injection. The presence of labelled T cells
in skin grafts were analyzed 24 hours later by wide-field
fluorescence microscopy.
As shown in Figure 7, inhibition of PI3K p110d activity either by
genetic mutation or pharmacological inhibition prevented HY-
specific T cell infiltration to male skin grafts. Theseresults suggest that
rejection of non-vascularized skin grafts relies upon inflammatory
mechanisms other than graft infiltration by antigen-specific T cells.
Discussion
In this study we have investigated the effect of genetic or
pharmacologic inactivation of PI3K p110d on the development of
chronic allograft rejection in a murine model of mHC (HY)-
mismatched heart allograft. We show that inhibition of PI3K
p110d activity significantly reduces the development of chronic
rejection by inhibiting memory T cell access to the allograft.
Following activation, efficient memory T cell localization to
antigen-rich sites requires a sequence of signals, mostly delivered
by the endothelium, which include tissue-selective homing
interactions such as those mediated by adhesion molecule and
chemokine ligand to reach and access target tissue [28,35]. We
and others have shown that efficient recruitment of antigen-
specific T cells into antigen-rich sites with promiscuous adhesion/
chemokine receptor/ligand pairs (such as the heart) is optimized
by TCR triggering of specific T cells by antigen-presenting
endothelium [19,20,28,36]. Importantly, this effect has been
shown to support the localization of effector T cells to mHC-
mismatched heart allograft leading to chronic rejection [28]. We
have also reported that antigen-dependent recruitment by the
endothelium strictly relies upon PI3K p110d activity, which is
initiated upon TCR triggering by MHC:peptide complexes
displayed on the endothelial surface[21].
In our study, the preventionof pathological inflammationleading
to chronic rejection by PI3K p110d inhibition correlated with
abrogation of antigen-specific T cell access to the transplanted
heart. In contrast, loss of PI3K p110d activity did not affect T cell
priming in our system, despite evidence suggesting that this
mediator is essential and non-redundant for TCR-induced
activation of both naı ¨ve and memory T cells [27]. While genetic
abrogation of PI3K p110d activity might have been compensated
for byalternative signalingpathways leading to T cell activation and
differentiation, pharmacologic inhibition of PI3K p110d post-
priming also appears to selectively affect T cell trafficking to the
heart without affecting T cell responsiveness. In the p110d
D910A
mouse, naive CD4
+ T cell proliferation and cytokine production is
particularly impaired under suboptimal stimulation conditions (e.g.,
in the absence of costimulation)[26]. It is possible that PI3K p110d
signals contributing to T cell activation might be dispensable when
antigen is not limiting, such as in transplantation settings.
The role of macrophages in the development of allograft
chronic rejection is still controversial [37–39]. In our study,
Figure 4. PI3K p110d is not required for constitutive trafficking
by antigen-specific T cells. PKH26-labelled HY-specific H2-A
b-
restricted CD4
+ WT and CFSE labelled HY-specific H2-A
b-restricted
p110d
D910A T cells were co-injected i.v. into female mice recipient of
syngeneic hearts. T cell localization in the liver, kidney, lymph node,
spleen, gut and native heart were assessed 24 hours later by wide-field
fluorescence microscopy. To minimize the effect of arbitrary choice of
field, tissue infiltration was quantified by randomly selecting ten610-
magnified fields from tissue samples from at least 3 animals and
assessing the number of fluorescent cells in each field. Each panel
shows a representative tissue image. The mean T cell infiltration 6 SD
observed in samples from at least 3 animals is shown.
doi:10.1371/journal.pone.0032892.g004
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32892Figure 5. Pharmacologic inhibition of PI3K p110d inhibits chronic heart rejection by preventing T cell access to the graft. Recipient
female WT mice received either syngeneic male or female heart grafts. After 7 days, the selective PI3K p110d inhibitor IC87114 (60mg/kg/day) or
vehicle control were injected i.p daily for 15 days. Mice were sacrificed 24 hours after the last treatment (day 23). (A) The mean histopathological
scores 6 SD of transplanted hearts stained with HE observed in 3 samples obtained from each recipient (at least 3 animals/group) is shown. 0, no
inflammation; 1, light focal lymphohistocytic infiltrate; 2, moderate focal lymphohistocytic infiltrate with myocardial involvement; 3, moderate to
severe inflammation with focal vasculopathy and myocyte degeneration; 4, severe inflammation, vasculopathy and myocardial fiber loss. **p,0.01 (B)
Both transplanted and native hearts were harvested and tissue sections were stained with either FITC-labelled anti-CD3 antibody or PE-labelled anti-
MAC2 antibody. The mean T cell infiltration 6 SD observed in samples from at least 3 animals is shown. Filled bar: transplanted heart; Non-filled bar:
native heart. *p,0.05. (C) PKH26-labelled HY-specific H2-A
b-restricted CD4
+ WT and CFSE labelled CD4
+ WT treated with IC87114 were injected i.v.
into female mice with male syngeneic heart transplantation. T cell localization in the transplanted heart and native heart were assessed 24 hours later
by wide-field fluorescence microscopy. Tissue infiltration was quantified by randomly selecting ten610-magnified fields from tissue samples from at
least 3 animals and assessing the number of fluorescent cells in each field. Each panel shows a representative tissue image. The mean T cell infiltration
6 SD observed in samples from at least 3 animals is shown. **p,0.01.
doi:10.1371/journal.pone.0032892.g005
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cantly) in both female (non-antigenic) and male heart transplants
compared to native hearts even in the absence of PI3K p110d
signaling, suggesting that PI3K p110d activity is not required for
monocyte recruitment. However, macrophage infiltration did not
affect the clinical outcome, suggesting that either macrophages do
not contribute to tissue damage in chronic heart allograft rejection
or that a cross talk with infiltrating T cells is necessary for
macrophage-mediated pathologic effects.
PI3K p110d inactivation did not affect HY-mismatched skin
rejection, despite inhibiting adoptively transferred HY-specific
effector T cell access to the skin graft. The immune responses
Figure 6. PI3K p110d inactivation does not prevent rejection of HY-mismatched skin. (A) Recipient female WT or p110d
D910A mice received
WT male skin grafts. Graft survival was monitored daily for up to 4 weeks. (B) Recipient female WT mice received male skin grafts. 7 days after
transplant, PI3K p110d inhibitor IC87114 at 60mg/kg/day or vehicle control were injected i.p daily until the grafts were rejected.
doi:10.1371/journal.pone.0032892.g006
Figure 7. PI3K p110d inactivation reduces skin graft infiltration by antigen-specific T cells. On day 20 post-skin grafting, PKH26 labelled
HY-specific 10x 10
6 WT and CFSE labelled 10
7 P110d
D910A T cells or WT T cells treated with PI3K p110d inhibitor IC87114 (5mM for 1 hour at 37uC) were
injected i.v. into recipient mice. T cell localization in male skin (A) and female skin (B) was assessed 24 hours later by wide-field fluorescence
microscopy. Tissue infiltration was quantified by randomly selecting ten610-magnified fields from at 3 tissue samples from at least 3 animal groups
and assessing the number of fluorescent cells in each field. The mean T cell infiltration 6 SD observed in samples from at least 3 animals is shown.
*p,0.05,* * p,0.01.
doi:10.1371/journal.pone.0032892.g007
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rely upon different immune mechanisms. First, HY-mismatched
heart grafts develop chronic T cell infiltrates and vasculopathy
over time but the organ remains viable and the heartbeat is
maintained. In contrast, HY-mismatched skin grafts fail on
average within 3 weeks of transplantation [28], suggesting that
the graft microenvironment (size and antigen presenting cells
richness) differently impacts on the strength of the alloresponse.
Second, anatomical vascular connection of heart allograft to the
host circulation is immediate, while connection of skin graft to the
host vascular system occurs within 2–3 weeks post grafting
[33,34,40], therefore T cell access to skin grafts is not regulated
by endothelial barriers at least in early rejection. Additionally,
heart graft endothelium remains of donor origin post grafting
[41,42], while skin graft re-vascularization partially relies upon
cells of host origin[33,34]. Most importantly, T cell-dependent
skin graft rejection can occur acutely in an antigen-independent
manner, as H-2b HY-specific, TCR transgenic Mata Hari CD8
+
T cells can efficiently reject H-2k skin but not heart allografts [28].
The immune pathway underlying TCR-independent skin rejec-
tion has been shown to depend on IFN-c[28], but its cellular and
molecular components have not yet been identified.
Hence,whilestillinhibiting specificT celltraffickinginto theskin,
the failure of PI3K p110d inactivation to improve skin graft survival
might be due to inflammation-induced mechanisms leading to by-
standing damage, related to the temporary lack of regulating
endothelial barrier and possibly triggered by overwhelming host
cross-reactive T cell responses against skin-harbored microbial
antigens. While the heart is contained within a sterile environment
inside the body, the skin is continuously exposed to environmental
microorganisms.
In summary, the observations described in this study strongly
support the concept that pharmacological inactivation of PI3K
p110d activity is a viable strategy to control heart allograft chronic
rejection. Additional advantages of this approach include the
possibility of inhibiting T-cell mediated inflammation in the
context of an established immune response (i.e. after transplan-
tation, as we have shown in this study), and the maintenance of
immune reactivity, which causes severe side-effect associated with
conventional immunosuppressive therapies. In this context, a
PI3K p110c?d dual selective inhibitor has been shown to
significantly reduce inflammatory injuries in vivo in heart
ischemia-reperfusion injury models in rat and pig, while at the
same time spare tissue repair processes such as EC mitogenesis
[43]. Clearly, the therapeutic application of PI3K p110d inhibition
will require careful planning dictated by the organ-specific
immunobiology of graft rejection. We propose that this strategy
would be very effective in the context of slow-developing T cell-
induced inflammation relying upon antigen-dependent trafficking
including chronic rejection of vascularized tissue grafts, such as
heart transplants, as well as other chronic, T-cell mediated
autoimmune diseases such as type I diabetes and multiple sclerosis.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the Home
Office recommendations and under its authority following approval
by the Imperial College London/Central Biomedical Services
Ethics Committee (REF. PPL 70/5872 and PPL 80/1842). All
surgery was performed under anesthesia and all efforts were made
to minimize suffering.
Animals
C57BL/6 mice were purchased from Harlan Olac (Bicester,
UK) and used at 7–11 weeks. p110d
D910A mice were generated as
previously described [26]. Experimental groups included 3–6
animals per group.
Cell culture
Memory CD4
+ T cells specific for the Y-chromosome encoded
HY peptide epitope NAGFNSNRANSSRSS and restricted by
H2-Ab [44] were obtained from WT and p110d
D910A mice by two
fortnightly i.p. immunizations of female mice with male C57BL/6
splenocytes, as previously described [45]. The two T cell
populations displayed similar specificity, as assessed by [
3H]thy-
midine incorporation, and phenotype, as established by flow
cytometry (Figure S5).
Reagents
The HY peptides encoding the Dby and Uty epitopes were
kindly provided by Dr. Jian Guo Chai (Imperial College, London,
UK). The PI3K p110d inhibitor IC87114 was synthesized as
described (D030 from patent WO 01/81346) [27]. IC87114
inhibits p110d kinase activity in cells with an IC50 between 0.1mM
and 0.5mM, and only shows cross-reactivity with other PI3K
isoforms at concentrations more than 5mM [27,46]. In vivo,
IC87114 was administered i.p. at a dose of 60 mg/kg. This dose
was chosen based on previous reports of its efficacy in vivo [47]. In
our hands, a 30 mg/kg by gavage achieves ,2 mM 90 min post-
administration and the drug is cleared from the blood 4–7 hours
post admin. IC87114 is selective for p110d at plasma concentra-
tions of 5 mM [47].
The cell linkers PKH26 and CFSE were purchased from Sigma-
Aldrich.
Flow cytometry
For surface staining, cells were labelled with the appropriate
concentration of fluorescence-conjugated antibodies or isotype
control according to the manufacturer’s instructions, and analyzed
by a two-laser BD fluorescence activated cell sorter (FACS)
Calibur (BD Biosciences, Oxford, UK). Acquired samples were
analyzed using Flowjo 7.6 (TreeStar Inc., UK).
T cell proliferation assays
T cells (10
4 /well) isolated from spleen were incubated with
irradiated female splenocytes (5610
5/well) and HY peptides Dby,
and Uty (0–100nM) in 96-well flat-bottomed plates. Plate was
pulsed 48 hours later with 1mCi/well [
3H] thymidine and
incubated overnight, then harvested using the Tomtec harvester
96 and filter and counted using the Wallac Microbeta counter for
Windows (all from Wallac/Perkin Elmer, Buckinghamshire, UK).
Heart transplantation
Heterotopic heart transplantation was performed in the
pathogen-free facilities at Northwick Park Institute for Medical
Research (NPIMR, UK) by placing the donor heart into the
recipient (WT and p110d
D910A) sternomastoid cavity, connecting
the aortal branch to the carotid artery and the pulmonary vein to
the jugular vein. Before surgery, mice were given 0.25ml Saline
s.c. to prevent dehydration. Anesthetic agents included Ketamine
(80–100mg/kg) and Xylazine 10mg/kg. These were administered
s.c. mixed in a syringe at a ratio of 2 (Ketamine):1 (Xylazine)
diluted with saline 1:1. For analgesia mice were given Rimadyl
(Carprofen 50mg/ml), diluted with saline 1:10 s.c.. at a dose of
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day one.
To assess the effect of pharmacological inhibition of PI3K
p110d activity on graft survival, WT recipients received the
selective inhibitor IC87114 at 60mg/kg/day or vehicle control i.p.
daily starting 7 days after transplantation and for 15 days.
At the indicated time points, all grafts and native hearts were
evaluated by histopathologic criteria in a single-blinded manner
(G. Stamp, Histopathology, Imperial College London) and scored
to grade the degree of inflammation from 0 to 4 [48] (0, no
inflammation; 1, light focal lymphohistocytic infiltrate; 2, moder-
ate focal lymphohistocytic infiltrate with myocardial involvement;
3, moderate to severe inflammation with focal vasculopathy and
myocyte degeneration; 4, severe inflammation, vasculopathy and
myocardial fiber loss).
Histochemistry
Five-micrometer-thick, paraffin-embedded sections were depar-
affinized, rehydrated in graded ethanol. For elastin staining,
sections were stained with Miller’s elastin followed by immuno-
peroxidase staining for smooth muscle cells (SMCs) using rabbit
monoclonal antibody to mouse SMC alpha actin (clone E184,
from Epitomics, California), then counterstained with hematoxy-
lin. For the purpose of comparison, tissue sections were taken in
corresponding regions of the heart (proximal ventricular areas).
Luminal occlusion was evaluated by tracing the cross-section of
each vessel’s internal elastic lamina and lumen using Lucia NIS
elements software (Nikon UK Ltd., United Kingdom) in three
transverse sections per graft. All vessels in each section, which
demonstrated clear staining of elastin laminar and presence of
SMC alpha-actin, were measured in three sections of each heart
[48]. For immunohistochemistry, tissue sections were incubated
for 1 h at room temperature with either FITC labelled anti-CD3
antibody or PE labelled anti-MAC2 antibody. Nucleus was
counterstained with Vectashield mounting medium for fluores-
cence with DAPI (Vector Laboratories). Cell infiltration was
evaluated by wide field microscopy and automated cell counting.
Skin grafting
Skin grafting was conducted by the method of Billingham and
Medawar [16] using tail skin from WT donors grafted onto the
lateral thorax of either WT or p110d
D910A female mice. Skin graft
rejection was assessed as previously described [49]. In the
experiments assessing the effect of pharmacological inhibition of
p110d activity on graft survival, WT recipients received the
selective inhibitor IC87114 at 60mg/kg/day or vehicle control i.p.
daily starting 7 days after transplantation and for 15 days. Prior to
surgery, mice received medetomidine (1mg/kg), ketamine (75mg/
kg) and atipamezole (2.5mg/kg) s.c..
Recruitment of circulating T cells into tissues
In adoptive transfer experiments HY-specific memory T cells
were incubated at 37uC for 10 minutes either with PKH26 (5 mM,
red) or CFSE (1 mM, green), washed 3 times with PBS and then
co-injected i.v. (10
7/mouse). After 24 hours, mice were sacrificed
and tissues were sampled and embedded in optimal cutting
temperature compound (CellPath Ltd, Newtown Powys). Tissue
infiltration by T cells was assessed by wide-field fluorescence
microscopy 24 hours after injection. The following combinations
were used: WT (red) and P110d
D910A (green) T cells, WT T cells
pre-treated with vehicle (1%DMSO, red) and with PI3K p110d
inhibitor IC87114 (5mM for 1 hour at 37uC, green).
Wide-field fluorescence microscopy and automatic cell
counting
Snap-frozen tissue sections were laid onto Polysine Microscope
slides (VWR International), and then mounted in Vectashield
mounting medium for fluorescence with DAPI (Vector Laborato-
ries), to stain the nuclei. Slides were visualized with a Coolview 12-
cooled CCD camera (Photonic Science) mounted over a Zeiss
Axiovert S100 microscope equipped with Metamorph software
(Zeiss). Tissue infiltration was quantified by randomly selecting ten
610-magnified fields from tissue samples from at least 3 animals
and assessing the number of fluorescent cells in each field.
Quantification of T cell infiltrates observed by wide-field fluores-
cence microscopy was performed using a specifically designed
software to run in the LabView (version 7.1; National Instruments)
environment. This automatic cell counting algorithm is based on a
combination of background subtraction, multiple thresholding, and
morphological processing approaches [50], which allow identifica-
tion of single fluorescent cells within the tissue. The number of
infiltrating labelled cells were then averaged and assessed
statistically. Infiltration is expressed as the mean of fluorescent cells
per 610 field in a given experimental condition 6 SD.
Statistics
Results are given as the mean per group 6 SD. The data were
analyzed using a two-tailed unpaired Student’s t test and Mann-
Whitney test. A P value of less than 0.05 was considered significant.
Supporting Information
Figure S1 Histology of transplanted and native hearts.
Recipient female WT and p110d
D910A mutant mice received either
male or female WT hearts. 23 days after transplant, both
transplanted and native hearts were harvested and stained with
hematoxilin/eosin. Each panel shows a representative tissue image.
Magnification: 20x.
(DOC)
Figure S2 Immunohistochemistry of transplanted and
native hearts. Recipient female WT mice received either
syngeneic male or female heart grafts. After 7 days, the selective
PI3K p110d inhibitor IC87114 (60mg/kg/day) or vehicle control
were injected i.p. daily for 15 days. Mice were sacrificed 24 hours
after the last treatment (day 23). (A) Both transplanted and native
hearts were harvested and stained with hematoxilin/eosin. Each
panel shows a representative tissue image. Magnification: 20x. (B)
Both transplanted and native hearts were harvested and tissue
sections were stained with either FITC-labelled anti-CD3 antibody
or PE-labelled anti-MAC2 antibody. Each panel shows a
representative tissue image. Magnification: 20x.
(DOC)
Figure S3 Pharmacologic inactivation of PI3K p110d
does not induce T cell tolerance. Recipient female WT mice
received either syngeneic male or female heart grafts. After 7 days,
the selective PI3K p110d inhibitor IC87114 (60mg/kg/day) or
vehicle control were injected i.p. daily for 15 days. Mice were
sacrificed 24 hours after the last treatment (day 23). Splenocytes
obtained from WT female recipients treated with or without
IC87114 were incubated with different concentrations of Dby and
Uty HY peptide epitopes for 48 hours, followed by pulsing with
[
3H] thymidine to assess T cell proliferation.
(DOC)
Figure S4 Genetic or pharmacologic inactivation of
PI3K p110d do not induce T cell tolerance in recipients
of skin allografts. (A) Recipient female WT and p110d
D910A
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rejected, splenocytes from recipient mice were harvested and
incubated with different concentrations of Dby and Uty HY
epitopes for 48 hours, followed by pulsing with [
3H] thymidine to
assess T cell proliferation. (B) Recipient female WT mice received
male skin grafts. 7 days after transplant, the PI3K p110d inhibitor
IC87114 at 60mg/kg/day or vehicle control were injected i.p.
daily until the grafts were rejected. Splenocytes from recipient
mice were harvested and incubated with different concentrations
of Dby and Uty HY epitopes for 48 hours, followed by pulsing with
[
3H] thymidine to assess T cell proliferation. Filled symbols: Dby;
Empty symbols: Uty.
(DOC)
Figure S5 Characterization of HY-specific WT and
p110d
D910A T cells. (A) HY-specific CD4
+ WT and
p110d
D910A T cells were harvested between days seven and ten
post-stimulation with irradiated male splenocytes. T cells were
stained with monoclonal antibodies recognizing CD4, CD8,
CD62L and CCR7 and appropriate isotype control antibodies
and analysed by flow cytometry. Expression of CD4, CD8,
CD62L and CCR7 is shown in bold while the dotted line
represents the isotype control. (B) WT or p110d
D910A T cells were
incubated with 6 x10
6 female irradiated splenocytes and different
concentrations of Dby (filled symbols) and Uty (empty symbols) HY
epitopes for 48 hours, followed by pulsing with [
3H] thymidine to
assess proliferation.
(DOC)
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